Document is current
Any future updates will be listed below
-
Authors
Zhu, Jun
Inomata, Takenori
Nakamura, Masahiro
Fujimoto, Keiichi
Akasaki, Yasutsugu
Fujio, Kenta
Yanagawa, Ai
Uchida, Koichiro
Sung, Jaemyoung
Negishi, Naoko
Nagino, Ken
Okumura, Yuichi
Miura, Maria
Shokirova, Hurramhon
Kuwahara, Mizu
Hirosawa, Kunihiko
Midorikawa-Inomata, Akie
Eguchi, Atsuko
Huang, Tianxiang
Yagita, Hideo
Habu, Sonoko
Okumura, Ko
Murakami, Akira
-
Funding
Funding for this research was provided by:
Sasakawa Medical Fellowship program (2018314)
Japan Society for the Promotion of Science (16K20332, 21K16884, 19K18041)
- License Information
-
More Information
Article History
Received: 29 October 2021
Accepted: 15 March 2022
First Online: 22 March 2022
Competing interests
: Dr. Zhu received funding from the Japan–China Sasakawa Medical Fellowship program (Grant Number 2018314) during the conduct of the study. Dr. Inomata received funding from JSPS KAKENHI (16K20332), JSPS KAKENHI (18K16935), and JSPS KAKENHI (20K09810) during the conduct of the study; funding and personal fees from Santen Pharmaceutical Co., Ltd.; and personal fees from InnoJin, Inc., funding from Johnson & Johnson Vision Care, Inc., HOGY MEDICAL Co., Ltd., Novartis Pharma K.K., Ribomic Co., Ltd., Kowa Company, Ltd., Lion Corporation, SEED Co., Ltd, Alcon Japan, Ltd., Rohto Pharmaceutical Co., HOYA Co., and WAKAMOTO Co., Ltd., outside the submitted work. Dr. Fujimoto received funding from JSPS KAKENHI (20K22985) and JSPS KAKENHI (21K16884) during the conduct of the study. Dr. Negishi received funding from JSPS KAKENHI (19K18041) during the conduct of the study. Dr. Okumura received personal fees from Innojin, Inc. outside the submitted work. Dr. Murakami received funding from Santen Pharmaceutical Co., Ltd., SEED Co., Ltd., Senju Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., AMO Japan K.K., HOYA Co., Ltd., Alcon Pharmaceuticals Ltd., Eisai Co., Ltd., Alcon Japan Ltd., Residence Building Management Co., Ltd., Kowa Company, Ltd., Novartis Pharma K.K., and ROHTO Pharmaceutical Co., Ltd. outside the submitted work. Dr. Nakamura, Dr. Akasaki, Dr. Fujio, Mrs. Yanagawa, Dr. Uchida, Mr. Sung, Dr. Nagino, Dr. Miura, Dr. Shokirova, Dr. Kuwahara, Dr. Hirosawa, Dr. Midorikawa-Inomawa, Dr. Eguchi, Dr. Huang, Dr. Yagita, Dr. Habu, and Dr. Okumura declare no competing interests.
